ExpreS2ion Biotech Holding AB (DE:5JD0)

FRANKFURT:5JD0

5JD0

ExpreS2ion Biotech Holding AB

RESEARCH TOOLSreports

Want to see DE:5JD0 full AI Analyst Report?

ExpreS2ion Biotech Holding AB (5JD0) Price & Analysis

2 Followers

5JD0 Stock Chart & Stats

€1.37

-€0.04(-2.01%)

At close: Jan 08 4:00 PM EST

€1.37

-€0.04(-2.01%)

Day’s Range― - ―

52-Week Range€0.07 - €0.88

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€5.98M

Enterprise Value-€40.54M

Total Cash (Recent Filing)€47.55M

Total Debt (Recent Filing)€2.21M

Price to Earnings (P/E)―

Beta2.14

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-13.66

Shares Outstanding23,398,983

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.89

Revenue Forecast (FY)€925.71K

Bulls Say, Bears Say

Bulls Say

Specialized Protein-expression PlatformExpreS2ion’s recombinant protein expression platform targets difficult-to-express antigens for vaccine and antibody R&D. That specialized capability creates higher barriers to entry, fosters repeat fee-for-service engagements, and supports durable client relationships in biopharma.

Low Financial LeverageReported debt-to-equity near 2–3% gives the company balance-sheet flexibility to fund development or weather losses without heavy interest expense. Low leverage preserves optionality for strategic partnerships or equity financing and reduces near-term solvency risk.

Reduced Cash Burn (2022–24)Management materially reduced cash burn into 2024, indicating improved discipline or cost control. Lowerized burn extends runway, increases time to secure partnerships or financing, and is a durable operational improvement if sustained alongside revenue stabilization.

Bears Say

Consistent Negative Cash FlowOperating and free cash flows are persistently negative and FCF worsened in 2025, forcing reliance on external funding. Chronic cash consumption increases dilution or refinancing risk and constrains the company’s ability to invest to scale its services or vaccine programs.

Small, Volatile And Declining RevenueTop-line is small, uneven and fell in consecutive recent years, limiting economies of scale and the ability to cover fixed R&D and manufacturing costs. Persistent revenue volatility undermines sustainable margin expansion and makes durable profitability harder to achieve.

Eroding Equity BaseMaterial contraction of equity and assets over 2021–2024 weakens the balance-sheet cushion against ongoing losses. Shrinking net assets reduce borrowing capacity, raise solvency concerns over time, and make future financing more dilutive or expensive.

5JD0 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was €0.07 and its highest was €0.88 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is €5.98M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 28, 2026 which is in 5 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -€0.079 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.079.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 23,398,983 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -€0.079 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.793%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in DE:5JD0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.